Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
Japan’s Central Social Insurance Medical Council (Chuikyo) has officially launched discussions on the FY2026 reform of the country’s cost-effectiveness assessment (CEA) system. One of the major focuses is on giving more clarity around the rules to designate or re-designate products…
To read the full story
Related Article
REGULATORY
- Japan Grants Sakigake Tag to Nanoscope’s MOGENRY
January 22, 2026
- MHLW Official Making Rounds to Rally Private Support for Drug Discovery Fund
January 21, 2026
- Cabinet OKs Subsidy to Boost Antibiotic API Stockpiles, Allocates 7.1 Billion Yen from Reserve
January 21, 2026
- PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations
January 21, 2026
- AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…